Search research articles
Contact Us
Filters
Showing results (11-20 of 28) with videos related to
Page
of 3
Sort By:
Future Oncology (London, England)
|
February 24, 2025
A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials
Paul Leger, Stanley Frencher, Jones T Nauseef, et al.
Scientific Reports
|
May 23, 2023
Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [<sup>18</sup>F]DCFPyL PET/CT in prostate cancer men
Kritika Subramanian, Juana Martinez, Sandra Huicochea Castellanos, et al.
The Prostate
|
January 24, 2025
Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis
Judith Stangl-Kremser, Andres Ricaurte-Fajardo, Sandra Huicochea Castellanos, et al.
The Prostate
|
July 10, 2023
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy
Judith Stangl-Kremser, Michael Sun, Benedict Ho, et al.
BMC Cancer
|
August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)
Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2023
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591
Scott T Tagawa, Charlene Thomas, A Oliver Sartor, et al.
JCO Precision Oncology
|
August 29, 2020
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations
Jose Mauricio Mota, Ethan Barnett, Jones T Nauseef, et al.
Cancer Treatment Reviews
|
May 4, 2024
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going
Miguel Muniz, Charles L Loprinzi, Jacob J Orme, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2026
Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
Bradley J Stish, Gina L Mazza, Jones T Nauseef, et al.
Nature
|
August 16, 2023
Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers
Jeremy Setton, Kevin Hadi, Zi-Ning Choo, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 28) with videos related to
Sort By:
Page
of 3
Future Oncology (London, England)
|
February 24, 2025
A multi-perspective study assessing Black and African American participation barriers in prostate cancer clinical trials
Paul Leger, Stanley Frencher, Jones T Nauseef, et al.
Scientific Reports
|
May 23, 2023
Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [<sup>18</sup>F]DCFPyL PET/CT in prostate cancer men
Kritika Subramanian, Juana Martinez, Sandra Huicochea Castellanos, et al.
The Prostate
|
January 24, 2025
Baseline Imaging Derived Factors of Response Following [225Ac]Ac-J591 Therapy in Metastatic Castration-Resistant Prostate Cancer: A Lesion Level Analysis
Judith Stangl-Kremser, Andres Ricaurte-Fajardo, Sandra Huicochea Castellanos, et al.
The Prostate
|
July 10, 2023
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy
Judith Stangl-Kremser, Michael Sun, Benedict Ho, et al.
BMC Cancer
|
August 23, 2023
Randomized phase II trial of MRI-guided salvage radiotherapy for prostate cancer in 4 weeks versus 2 weeks (SHORTER)
Ariel E Marciscano, Sydney Wolfe, Xi Kathy Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2023
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of <sup>225</sup>Ac-J591
Scott T Tagawa, Charlene Thomas, A Oliver Sartor, et al.
JCO Precision Oncology
|
August 29, 2020
Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations
Jose Mauricio Mota, Ethan Barnett, Jones T Nauseef, et al.
Cancer Treatment Reviews
|
May 4, 2024
Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going
Miguel Muniz, Charles L Loprinzi, Jacob J Orme, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 26, 2026
Alliance A222001: Oxybutynin Versus Placebo for the Treatment of Hot Flashes in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer
Bradley J Stish, Gina L Mazza, Jones T Nauseef, et al.
Nature
|
August 16, 2023
Long-molecule scars of backup DNA repair in BRCA1- and BRCA2-deficient cancers
Jeremy Setton, Kevin Hadi, Zi-Ning Choo, et al.
Page
of 3